RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCsFurther to Dr. Vile's specific comment to direct question on pelareorep and ADCs during the June 5, 2023 KOL meeting.
Pelareorep's ability to remodel an otherwise immunosuppressive tumor microenvironment (TME), along with pelareorep's ability to 'prime' the innate and adaptive immune system, and pelareorep's 'fine' boosting capability are mechanisms that benefit the enhancement of both anti-body drug conjugates (ADC) and CAR-T therapies thus making both Pfizer and Roche significantly interested players in ONCY's potential acquisition.